全文获取类型
收费全文 | 6762篇 |
免费 | 534篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 188篇 |
妇产科学 | 154篇 |
基础医学 | 887篇 |
口腔科学 | 66篇 |
临床医学 | 818篇 |
内科学 | 1249篇 |
皮肤病学 | 143篇 |
神经病学 | 847篇 |
特种医学 | 112篇 |
外科学 | 782篇 |
综合类 | 65篇 |
一般理论 | 9篇 |
预防医学 | 744篇 |
眼科学 | 145篇 |
药学 | 528篇 |
中国医学 | 6篇 |
肿瘤学 | 504篇 |
出版年
2024年 | 15篇 |
2023年 | 141篇 |
2022年 | 175篇 |
2021年 | 398篇 |
2020年 | 204篇 |
2019年 | 320篇 |
2018年 | 324篇 |
2017年 | 218篇 |
2016年 | 281篇 |
2015年 | 285篇 |
2014年 | 346篇 |
2013年 | 407篇 |
2012年 | 635篇 |
2011年 | 602篇 |
2010年 | 292篇 |
2009年 | 267篇 |
2008年 | 406篇 |
2007年 | 393篇 |
2006年 | 381篇 |
2005年 | 315篇 |
2004年 | 284篇 |
2003年 | 215篇 |
2002年 | 191篇 |
2001年 | 19篇 |
2000年 | 23篇 |
1999年 | 12篇 |
1998年 | 19篇 |
1997年 | 21篇 |
1996年 | 11篇 |
1995年 | 13篇 |
1994年 | 8篇 |
1993年 | 8篇 |
1992年 | 9篇 |
1991年 | 10篇 |
1990年 | 7篇 |
1989年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1975年 | 3篇 |
1974年 | 5篇 |
1972年 | 2篇 |
1964年 | 2篇 |
1963年 | 2篇 |
1925年 | 1篇 |
排序方式: 共有7315条查询结果,搜索用时 15 毫秒
41.
42.
Natalie A. Winings Brian J. Daley Reagan W. Bollig R. Frank Roberts Jennifer Radtke R. Eric Heidel Jessica E. Taylor James C. McMillen 《The surgeon》2021,19(3):129-134
Backgroundand Purpose: Currently, dexmedetomidine versus propofol has primarily been studied in medical and cardiac surgery patients with outcomes indicating safe and effective sedation. The purpose of this study was to assess the efficacy of dexmedetomidine versus propofol for prolonged sedation in trauma and surgical patients.MethodsThis was a single-center prospective study conducted in the Trauma/Surgical Intensive Care Unit (ICU) at a Level I academic trauma center. It included patients 18 years of age or older requiring mechanical ventilation who were randomly assigned based on unit bed location to receive either dexmedetomidine or propofol. The primary outcome was duration of mechanical ventilation. Secondary outcomes included mortality; proportion of time in target sedation; incidence of delirium, hypotension, and bradycardia; and ICU and hospital length of stay (LOS).ResultsA total of 57 patients were included. Baseline characteristics were similar between groups. There was no significant difference in duration of mechanical ventilation (median [IQR]) between the dexmedetomidine (78.5[125] hours) and propofol (105[130] hours; p = 0.15) groups. There was no difference between groups in ICU mortality, ICU and hospital LOS, or incidence of delirium. Safety outcomes were also similar. Patients in the dexmedetomidine group spent a significantly greater percentage of time in target sedation (98[8] %) compared to propofol group (92[10] %; p = 0.02).ConclusionsOur results suggest that, similar to medical and cardiac surgery patients, dexmedetomidine and propofol are safe and effective sedation agents in critically ill trauma and surgical patients; however, dexmedetomidine achieves target sedation better than propofol for this specific population. 相似文献
43.
44.
Terzikhan Natalie Hofman Albert Goudsmit Jaap Ikram Mohammad Arfan 《European journal of epidemiology》2021,36(3):319-324
European Journal of Epidemiology - Initial results from various phase-III trials on vaccines against SARS-CoV-2 are promising. For proper translation of these results to clinical guidelines, it is... 相似文献
45.
46.
Sarah Wang Lina Patel Elise A. Sannar Mellad Khoshnood Natalie K. Boyd Lorena Mendez Noemi A. Spinazzi Eileen A. Quinn Michael S. Rafii Jonathan D. Santoro 《American journal of medical genetics. Part A》2023,191(7):1769-1782
Down syndrome regression disorder (DSRD) is a clinical symptom cluster of acute or subacute neurocognitive regression in otherwise health persons with Down syndrome. The objective of this study was to evaluate if adverse childhood experiences (ACEs) were more prevalent in children with DSRD than those with DS alone. A survey-based, cohort-based study was performed. Caregivers of individuals with DSRD with onset of symptoms between age 10 and 30 years and DS alone were administered the ACEs questionnaire via an online REDCap survey. A total of 159 responses were collected after excluding incomplete surveys and those not meeting criteria for DSRD. Individuals with DSRD were not more likely to experience ACEs (p = 0.18, 95% confidence interval [CI]: 0.43–1.17). In those with ACEs prior to the onset of symptoms, the median time prior was 7 months (interquartile range: 5–10). Individuals with DSRD were more likely to report three or more ACEs (52, 33%) compared to those with DS alone (39, 22%) (p = 0.02, 95% CI: 1.08–2.87). Exposure to ACEs were not predictive of response to particular therapeutic interventions although those with multiple ACEs 3 months prior to the onset of symptoms was associated with lower response rates to benzodiazepines and immunotherapy (p = 0.02, 95% CI: −3.64–−1.13). This study provides preliminary data that individuals with DSRD experience ACEs at a similar rate to individuals with only DS alone, although three or more ACEs, often preceding the onset of symptoms, was more prevalent in individuals with DSRD. 相似文献
47.
Natalie Baziuk Charles M. Gremillion Jr. Gholam A. Peyman Ho Kyun Cho 《International ophthalmology》1992,16(2):101-107
Five albino New Zealand rabbits underwent bilateral lensectomy and vitrectomy. All left eyes were fitted with a collagen shield that had been soaked for 5 min in 2.0 mL of gentamicin solution (40 mg/mL for IV use). Right eyes were treated with fortified gentamicin drops (13.6 mg/mL) every 30 min for 12 hrs. Aqueous and vitreous specimens were obtained at the following time intervals: 1, 2, 4, 8, 12 and 24 hrs.We found the gentamicin concentrations to be higher in the aqueous of all eyes treated with fortified gentamicin drops. Only those eyes treated with fortified gentamicin drops attained a therapeutic drug level (4g–9g/mL) in the aqueous. Therapeutic drug levels were not attained in the vitreous of either treatment group. 相似文献
48.
Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. 总被引:1,自引:0,他引:1
49.
Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. 总被引:14,自引:0,他引:14
Natalie Reimers Kristine Zafrakas Volker Assmann Cornelia Egen Lutz Riethdorf Sabine Riethdorf Jürgen Berger Sebastian Ebel Fritz J?nicke Guido Sauter Klaus Pantel 《Clinical cancer research》2004,10(10):3422-3428
PURPOSE: EMMPRIN (extracellular matrix metalloprotease inducer) is a glycosylated member of the immunoglobulin superfamily known to stimulate the production of matrix metalloproteases (MMPs) 1, 2, and 3 and MT1-MMP in peritumoral fibroblasts. We here evaluated whether EMMPRIN expression is related to tumor progression in human breast cancer. EXPERIMENTAL DESIGN: An immunohistochemical study using high-density tissue microarrays (n = 2222 breast cancer samples) and EMMPRIN-specific antibodies HIM6 and MEM-M6/1 was performed, and staining results were statistically correlated with various clinicopathological parameters. To analyze the putative association between EMMPRIN expression and bone marrow (BM) micrometastasis, an additional set of 55 breast tumors from patients with or without micrometastatic cells as determined with anti-cytokeratin antibody A45-B/B3 were included in our study. Cytokeratin-positive cells in BM were costained with EMMPRIN-specific antibody 1G6.2. RESULTS: Positive EMMPRIN staining correlated significantly with various histopathological risk factors (higher tumor grade, increased tumor size, negative estrogen receptor status and progesterone receptor status, and higher mitotic index) as well as decreased tumor-specific survival (log-rank, P = 0.0027). In particular, in patients > 50 years (i.e., postmenopausal women), EMMPRIN expression was an independent prognosticator as shown by Cox regression analysis (relative risk = 1.7, 95% confidence interval 1.4-4.3, P = 0.036). An involvement of EMMPRIN in tumor progression was also supported by the fact that it was expressed on approximately 90% of micrometastatic cells in BM. CONCLUSIONS: EMMPRIN expression in primary tumor predicts an unfavorable prognosis in breast cancer, suggesting a crucial role of EMMPRIN in progression of human mammary carcinomas. 相似文献
50.
Natalie A. Betz Heideh K Fattaey Brenda A. Westhoff Avelina Q. Paulsen Terry C. Johnson 《Breast cancer research and treatment》1997,42(2):137-148
Very few growth inhibitors have been identified whichcan inhibit the proliferation of a broad spectrumof human breast cancer cell lines. CeReS-18, anovel cell surface sialoglycopeptide growth inhibitor, can reversiblyinhibit the proliferation of both estrogen receptor positive(MCF-7) and negative (BT-20) human breast cancer celllines. In addition, at concentrations above those requiredfor the reversible inhibition of cell proliferation, CeReS-18can also induce cell death in MCF-7 cells.Changes in nuclear and cytoplasmic morphology, characteristic ofapoptosis, were detected in MCF-7 cells treated witha cytotoxic concentration of CeReS-18, and internucleosomal DNAcleavage was also observed. The sensitivity of MCF-7and BT-20 cells to the biological properties ofCeReS-18 could be influenced by altering the calciumconcentration in the extracellular growth medium, such thatwhen the calcium concentration in the environment wasdecreased, an increased sensitivity to CeReS-18-induced growth inhibitionand cytotoxicity were observed. The addition of thecalcium chelating agent EGTA to MCF-7 cells, culturedin a normal calcium environment, could mimic theincreased sensitivity to the biological effects of CeReS-18observed under reduced calcium conditions. 相似文献